Gut Microbiome–SCFA Axis as a Pharmacodynamic Modifier of GLP-1 Receptor Agonist Therapy in the South Asian Metabolic Phenotype

Fundraise closed

Shibichakravarthy Kannan

Gut Microbiome–SCFA Axis as a Pharmacodynamic Modifier of GLP-1 Receptor Agonist Therapy in the South Asian Metabolic Phenotype

Funding· Closed

$11of $10,000

Reviewed by2

Key insightsBeta

GUTMAP-SA is a 24-week prospective observational cohort (N=100 GLP-1RA initiators plus 30 controls) testing whether a baseline microbiome SCFA Composite Score predicts HbA1c reduction in South Asians, a population missing from pivotal trials. Strengths include a clear gap, rigorous assays, and FAIR plan; key risks are a narrow two-taxon biomarker, mixed GLP-1RA agents confounding inference, and an unnamed multidisciplinary team.

Important Population Gap
Rigorous Methods
Narrow Biomarker
Agent Heterogeneity

Funding· Closed

$11of $10,000

Reviewed by2

Key insightsBeta

Important Population Gap
Rigorous Methods
Narrow Biomarker
Agent Heterogeneity

Drafts

Gut Microbiome–SCFA Axis as a Pharmacodynamic Modifier of GLP-1 Receptor Agonist Therapy in the South Asian Metabolic Phenotype

Drafts

Drafts

Gut Microbiome–SCFA Axis as a Pharmacodynamic Modifier of GLP-1 Receptor Agonist Therapy in the South Asian Metabolic Phenotype

Reviewed by2

Key insightsBeta

Reviewed by2

Key insightsBeta